Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 21:11:628243.
doi: 10.3389/fonc.2021.628243. eCollection 2021.

Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment

Xiaohu Zheng  1   2 , Haiming Wei  1   2   3
Affiliations
Review

Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment

Xiaohu Zheng et al. Front Oncol. .

Abstract

Anti-PD-1 therapy has revolutionized the clinical treatment of lung cancer. With the increasing number of lung cancer patients being treated, there is also an increase in the number of immune-related adverse events (irAEs) being reported. These irAEs involve multiple organs and systems, mainly manifest as inflammatory side effects, and are different from the adverse events observed with traditional lung cancer treatment. These effects are often mild and treatable and reversible; however, in a few cases the side effects can be severe and lead to termination of immunotherapy. Management involves glucocorticoid-based related immunomodulators, which should be carefully prescribed to balance the efficacy and side effects of the PD-1 antibody treatment. This review will describe the characteristics and mechanisms of irAEs in specific organs, and will serve as a guide to help optimize treatment plans and improve patient outcomes.

Keywords: PD-1 antibody therapy; immune-related adverse events (irAE); inflammatory; lung cancer; side effect.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Organ-specific immune-related adverse events by PD-1 blockade in lung cancer treatment. The incidence rates are shown.
See this image and copyright information in PMC

References

    1. Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-Related Adverse Events of Checkpoint Inhibitors. Nat Rev Dis Primers (2020) 6:38. 10.1038/s41572-020-0160-6 - DOI - PMC - PubMed
    1. Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, et al. Immune-Related Adverse Events for anti-PD-1 and anti-PD-L1 Drugs: Systematic Review and Meta-Analysis. Bmj (2018) 360:k793. 10.1136/bmj.k793 - DOI - PMC - PubMed
    1. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the Treatment of non-Small-Cell Lung Cancer. New Engl J Med (2015) 372:2018–28. 10.1056/NEJMoa1501824 - DOI - PubMed
    1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab Versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. New Engl J Med (2015) 373:1627–39. 10.1056/NEJMoa1507643 - DOI - PMC - PubMed
    1. Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, et al. Nivolumab Monotherapy for First-Line Treatment of Advanced non–Small-Cell Lung Cancer. J Clin Oncol (2016) 34:2980–7. 10.1200/JCO.2016.66.9929 - DOI - PMC - PubMed

LinkOut - more resources